Background

Senescent cells exhibit a functional dichotomy: in acute injury they act as chaperones that promote tissue repair, whereas chronic accumulation turns them into witnesses of unresolved damage that drive inflammation and fibrosis. Transient p16+/p21+ senescent fibroblasts secrete PDGF‑AA to accelerate wound closure and limit fibrosis [2], recruit immune cells for clearance [3], and can upregulate Fas ligand to kill infiltrating immune cells [6]. When senescence persists, these cells shift toward protumor functions via STAT3 activation [5] and create immunosuppressive microenvironments. The problem is not senescence per se but the failure to clear these cells after their temporary repair mission [1,7,8,9].

Hypothesis

The beneficial chaperone function of transient senescent fibroblasts depends on their ability to transfer healthy mitochondria to neighboring progenitor cells via tunneling nanotubes (TNTs) and extracellular vesicles. This mitochondrial transfer sustains progenitor proliferation, supports matrix remodeling, and restrains fibrosis. Chronic senescent cells lose this capacity due to mitochondrial DNA damage and elevated reactive oxygen species, converting their secretory profile from pro‑regenerative to pro‑inflammatory and immunosuppressive.

Mechanistic Rationale

• Transient senescent fibroblasts exhibit a SASP enriched in PDGF‑AA and chemotactic factors that attract immune cells [2,3]; we propose that alongside these soluble signals they also donate functional mitochondria to support the metabolic needs of responding fibroblasts and endothelial cells.
• Mitochondrial transfer has been demonstrated in stromal stem cell niches and is known to enhance tissue repair after injury (general principle). Senescent cells retain intact mitochondria early in the senescence program, but cumulative oxidative stress damages mtDNA, impairing transfer competence.
• Loss of mitochondrial transfer reduces ATP supply to neighboring cells, shifting them toward a glycolytic, pro‑fibrotic phenotype and diminishing their ability to clear matrix debris, thereby exacerbating fibrosis.
• Concurrently, stressed senescent mitochondria release mitochondrial DNA and formyl peptides that act as damage‑associated molecular patterns (DAMPs), amplifying inflammasome activation and reinforcing a chronic inflammatory SASP.

Predictions

1. Enhancing mitochondrial transfer from senescent fibroblasts (e.g., by overexpressing Miro1 or using low‑dose cytochalasin D to promote TNT formation) will improve wound closure and reduce fibrosis in young mice, even without senolytic clearance.
2. Inhibiting mitochondrial transfer (with TNT blockers such as nocodazole or Miro1 knockdown) will delay healing, increase fibrosis, and elevate pro‑inflammatory cytokines, despite the presence of senescent cells.
3. The combination of a senolytic (e.g., navitoclax) and a mitochondrial transfer enhancer will not produce additive benefits over the enhancer alone, indicating that the enhancer captures the key therapeutic contribution of senescent cells.
4. In aged mice, baseline mitochondrial transfer from senescent cells will be low; pharmacologically boosting transfer will restore a youthful‑like healing profile.

Experimental Design

• Animal model: Full‑thickness excisional wounds on dorsal skin of young (8‑week) and aged (20‑month) mice.
• Groups (n=8 per group):
  1. Vehicle control
  2. Senolytic (navitoclax, intermittent dosing)
  3. Mitochondrial transfer enhancer (AAV9‑Miro1 fibroblast‑specific overexpression)
  4. TNT inhibitor (nocodazole topical application)
  5. Senolytic + enhancer
  6. Senolytic + inhibitor
  7. Enhancer + inhibitor (to test specificity)
  8. Isotype control AAV
• Mitochondrial labeling: Prior to wounding, isolate fibroblasts from GFP‑mtDNA reporter mice, transplant GFP‑marked senescent fibroblasts into wound beds to track transfer.
• Readouts (day 3, 7, 14 post‑wound):
  • Wound area reduction (% closure) by planimetry.
  • Histology: Masson’s trichrome for collagen deposition (fibrosis), immunofluorescence for α‑SMA (myofibroblasts).
  • Immune infiltrate: Flow cytometry for Ly6G+ neutrophils, F4/80+ macrophages, CD8+ T cells.
  • SASP profiling: Luminex cytokine panel (IL‑6, IL‑1β, TGF‑β, PDGF‑AA).
  • Mitochondrial transfer quantification: qPCR for GFP‑mtDNA in recipient cells; confocal microscopy for GFP signal transfer.
  • Senescence verification: p16Ink4a and SA‑β‑gal staining.

Potential Outcomes and Interpretation

• If the hypothesis is correct: The enhancer group will show accelerated closure (~30% faster than control), reduced fibrosis (~40% less collagen), increased GFP‑mtDNA transfer to neighboring cells, and a SASP shifted toward regenerative factors (↑PDGF‑AA, ↓IL‑6). Senolytic alone will improve outcomes but not surpass the enhancer; the combination will not be additive. Inhibitor groups will display delayed healing, elevated fibrosis, and heightened inflammatory cytokines despite senolytic treatment. Aged mice receiving the enhancer will recover youthful‑like closure rates and transfer levels.
• If the hypothesis is false: Enhancing mitochondrial transfer will not affect wound metrics; senolytics will remain the only effective intervention; transfer inhibition will not worsen healing beyond senolytic effects.

Implications

This work reframes senescent cells not merely as targets for elimination but as dynamic bioenergetic hubs whose mitochondrial output sustains regeneration. Therapeutic strategies that bolster mitochondrial transfer from transient senescent cells could preserve their chaperone function while mitigating the need for broad senolytic clearance, reducing off‑target toxicity and preserving tissue surveillance. It also suggests that biomarkers of mitochondrial transfer competence (e.g., Miro1 activity, mtDNA integrity) may predict when senescence is beneficial versus harmful, guiding personalized senomorphic or senolytic regimens.